Maxcyte Inc’s (LON:MXCT) technology for engineered cell mechanisms is to be used by Nasdaq-listed genome specialist Editas Medicine for diseases such as sickle cell anaemia and blood disorders.
Through the non-exclusive deal, Editas has clinical and commercial rights to MaxCyte's Flow Electroporation and ExPert platforms to develop up to five therapies including four in immuno-oncology.
These include EDIT-301, an experimental Crispr medicine designed to durably treat sickle cell disease and blood illness beta-thalassemia.
In return, MaxCyte will receive development and approval milestones and sales-based payments alongside outside licensing fees.
"We look forward to working with MaxCyte and using its leading technology to develop EDIT-301 as a best-in-class medicine for the treatment of sickle cell disease and beta-thalassemia, and for up to four engineered cell medicines to treat cancer," said Charles Albright, Editas’s chief scientific officer.
Editas is a US$1bn gene-editing company that uses the Crispr genome editing system to modify gene functions to tackle a range of diseases.
Doug Doerfler, MaxCyte’s chief executive, said Editas it is at the forefront of developing engineered cell medicines and he is excited to be working with such a pioneering business.
Maxcyte’s flow electroporation and ExPert technologies allow delivery of virtually any molecule, to any cell, at any scale with minimal disturbance to the cells.